Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Phase 2b Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

NCT07281937 is registered in ClinicalTrials.gov with Verdiva Bio Dev Limited as lead sponsor.

NCT NCT07281937
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07281937 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Phase 2b Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
Lead sponsor
Verdiva Bio Dev Limited
Phase
Phase 2
Overall status
Completed
Start date
November 25, 2025
Completion date
July 23, 2026
Enrollment
206 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

obesity, overweight